A2A designs novel pre-optimized therapeutics for cancer and infectious disease using proprietary software. Data from in-vitro leukemia testing is very good.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free